Janssen-Cilag International NV announced promising interim results from the Phase 2b SunRISe-1 study (Cohort 4) of TAR-200, a gemcitabine-releasing system for bladder cancer. The treatment showed high disease-free survival (DFS) rates (over 80% at nine months) in patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary disease, allowing 94% of patients to avoid bladder removal. These results were presented at the 2025 American Urological Association Annual Meeting.
This news is potentially transformative for patients with HR-NMIBC who have historically faced limited options beyond radical cystectomy, a life-altering surgery. The high DFS and bladder preservation rates observed with TAR-200 suggest a less invasive and potentially more effective treatment alternative, significantly improving patient quality of life. This development could represent a major shift in the standard of care for this patient population.
Interim analysis from Cohort 4 showed DFS rates of 85.3% at six months and 81.1% at nine months. The high rates were consistent across both high-grade Ta and T1 disease subtypes, suggesting effective tissue penetration of the drug. Progression-free survival and overall survival at nine months were also encouraging at 95.6% and 98%, respectively. The safety profile of TAR-200 was consistent with previous studies, with most treatment-related adverse events being low-grade and transient.
These positive Phase 2b results support the ongoing Phase 3 SunRISe-5 study, which compares TAR-200 to standard chemotherapy. If the Phase 3 trial confirms these findings, TAR-200 could become a new standard of care for BCG-unresponsive HR-NMIBC, offering patients a bladder-preserving treatment option with a favorable safety profile. This could significantly reduce the number of radical cystectomies performed and ultimately improve the lives of individuals diagnosed with this challenging form of bladder cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
